(Stroke. 2001;32:1425.)
© 2001 American Heart Association, Inc.
Comments, Opinions, and Reviews |
From the Departments of Medical Decision Making (P.N.P., A.M.S., P.P.W.) and Vascular Surgery (P.N.P.), Leiden University Medical Center (Netherlands).
Correspondence to Piet N. Post, MD, PhD, Department of Medical Decision Making, Leiden University Medical Center (K6R), PO Box 9600, 2300 RC Leiden, Netherlands. E-mail P.N.Post{at}lumc.nl
| Abstract |
|---|
|
|
|---|
Summary of ReviewWe searched various databases for articles reporting empirical assessment of utilities. Mean utilities of major stroke (Rankin Scale 4 to 5) and minor stroke (Rankin Scale 2 to 3) were calculated, stratified by study population and elicitation method. Additionally, the modified Rankin Scale was mapped onto the EuroQol classification system. Utilities were obtained from 23 articles. Patients at risk for stroke assigned utilities of 0.26 and 0.55 to major and minor stroke, respectively. Stroke survivors assigned higher utilities to both major (0.41) and minor stroke (0.72). The EuroQol completed by stroke survivors revealed a utility of 0.32 and 0.71 for major and minor stroke, respectively. Utilities elicited by the Standard Gamble were generally higher, while those obtained by the Visual Analogue Scale were lower than the Time Trade Off values. Remaining variation between utilities may be caused by differences in definitions of the health states. The mapped EuroQol indicated a utility of 0.64 for minor stroke and a value just below zero for major stroke.
ConclusionsFor minor stroke, a utility between 0.50 and 0.70 seems to be reasonable for both decision analyses and cost-effectiveness studies. The utility of major stroke may range between 0 and 0.30 and may possibly be negative.
Key Words: cost-benefit analysis decision analysis outcome quality of life
| Introduction |
|---|
|
|
|---|
There have been many debates on the appropriate population from which utilities should be elicited. It has been argued that the healthy community is appropriate for cost-effectiveness analyses from the societal perspective and that patients at risk for stroke are more suited for decision analyses from the patients perspective.8 Nonetheless, the effect of the type of study population on utility scores for stroke has not been studied extensively. Hallan et al9 elicited utilities from 3 different study populations and reported a utility of 0.54 for major stroke (at ages 45 to 64 years) for healthy people but a utility of up to 0.85 for stroke survivors.
We performed a systematic review of the literature on the utility of stroke and explored the impact of the study population and the elicitation method on the utility estimates. We compared these estimates with utilities obtained by the EuroQol classification system.
| Methods |
|---|
|
|
|---|
We examined the reference lists of all included articles for other relevant references. Furthermore, we contacted experts in the field to obtain published or unpublished studies reporting assessments of utilities for stroke.
Articles were included if utilities for stroke had been elicited. The articles were required to include the following in the Methods section: (1) a description of the study population and (2) a description of the method of utility elicitation. The first author did the first selection of articles through the electronic databases. The exclusion criteria were applied by 2 authors (P.N.P. and P.P.W.), who also abstracted the information, mutually independent and blinded. Disagreements were resolved through discussions. We grouped the articles according to the study population into the following categories: healthy participants, patients at risk for stroke, or stroke survivors.
The utilities for major as well as minor disability after stroke were examined. These 2 states were distinguished by the modified Rankin Scale.10 Minor stroke corresponded to Rankin Scale grade 2 to 3 (minor or moderate handicap; some or significant restrictions in lifestyle), and major stroke corresponded to Rankin Scale grade 4 to 5 (moderately severe or severe handicap; precludes independent existence). If stroke survivors were asked to value their own health state, we sought to obtain information about the degree of disability of these patients. We matched the health states used in the included publications as much as possible with those described above. However, we included the utility in the "unspecified stroke" category whenever the degree of severity had not been specified. If utilities in 1 study were assessed among 2 or more groups of participants, the group sizeweighted mean of these utilities was taken.
It is incorrect to compare a utility assessed with the use
of death as the lower reference point with a utility that uses another
lower reference point. The same holds true for an upper reference point
other than perfect health. Therefore, when death was not assigned a
utility of 0 or perfect health was not assigned a utility of 1,
utilities were normalized according to the
following:
![]() |
Additionally, the authors scored the EuroQol according to the health state described by the modified Rankin Scale for both major and minor stroke.10
| Results |
|---|
|
|
|---|
|
Stroke survivors assigned higher values to this health state
than patients at risk for stroke or healthy participants
(Table 2
). Patients at risk for stroke assigned
slightly lower utilities than healthy participants. The utility of an
unspecified stroke was on average close to the utility of minor stroke.
Utilities elicited by TTO were generally lower than SG utilities. VAS
and HUI utilities were lower than TTO utilities.
|
Part of the variation may be explained by differences in the
health states descriptions. As is shown in
Table 3
, considerable variation could be observed in
the description of the particular health states. Therefore, the mean
utilities in
Table 2
should be considered with care. From
Table 3
, utilities for more specific stroke states can be
read. Whereas the utility of hemiplegia is 0.28 according to Adar et
al,11 it is 0.13 if aphasia
is coexistent. A severe motor deficit has the lowest
utility (-0.08) according to Solomon et
al,12 followed by -0.02
for a severe cognitive deficit and 0.06 for a severe language
deficit.
|
The EuroQol, as completed by the authors, indicated a very
low, even negative, utility of major stroke
(Table 2
). For minor stroke, the EuroQol revealed a utility
similar to that elicited from healthy participants or patients at risk
for stroke.
| Discussion |
|---|
|
|
|---|
Study Population
Whereas the utility of major stroke assigned by healthy
participants was fairly similar to that assigned by patients at risk
for stroke, stroke survivors generally assigned higher utilities. It is
a common finding that patients actually experiencing an impaired health
state evaluate it higher than other people. This is generally explained
by psychological processes such as coping and
adaptation.14 Moreover,
since severely ill patients cannot be included in studies assessing
utilities, the utility of stroke may be spuriously increased if
assigned by stroke survivors because of selection bias.
In 2 studies, stroke survivors also assigned higher utilities to hypothetical stroke states than healthy participants9 or subjects at risk for stroke.15 In contrast, Adar et al11 observed fairly similar utilities for stroke survivors and healthy participants.
There have been many debates on which group of subjects should be used to elicit utilities for various decisions. Patients who have experienced stroke know best what life after stroke entails. They are, however, not the people facing the decisions regarding stroke. Gold et al8 suggested that utilities to be used in cost-effectiveness analyses from the societal perspective are best elicited from the general public because policy decisions concern the money of the general public. They suggested that utilities for clinical decisions are better inferred from patients. In the latter case, patients at risk are most similar to patients at the moment of decision; hence, if such similarity is deemed important, the utilities of patients at risk for stroke may be deemed most appropriate.
Elicitation Method
In general, it has been found that SG scores are higher
than TTO scores, which in turn are higher than VAS
scores.16 Our results are in
agreement with this general finding. Two studies elicited utilities
from the same study populations by 2 different methods. Hallan et
al9 observed the highest
utility for SG (0.61), followed by TTO (0.51) and VAS (0.31). Gage et
al17 observed a higher
utility for major stroke when elicited by SG (0.26) than by TTO
(0.11).
An explanation for these findings may be as follows. The SG method is prone to a number of biases, such as probability transformation, which can lead to large overestimations.18 The method is also cognitively demanding. VAS scores do not relate to tradeoffs and decisions and hence are less valid for decision making. TTO scores do not consider risk or discounting but are not prone to extreme biases. For these reasons the TTO scores are presently most frequently used in medical decision making, and we also recommend their use.
Health State Descriptions
It is likely that variations in health state
descriptions play a role in the variation between the reported
utilities because various definitions were used to describe minor or
major stroke. Moreover, if specific negative aspects of stroke are
explicitly included in the definition, participants tend to judge this
health state as less desirable. Adar et
al11 reported a lower
utility when aphasia was included in the description of major stroke
(in addition to hemiplegia). Solomon et
al12 observed a paramount
aversion to a severe motor impairment. A severe cognitive deficit also
elicited a negative utility, and a severe language deficit received a
utility of just above zero.
The utility of major stroke obtained by completion of the EuroQol was lower than that reported by studies that used healthy participants to elicit utilities. It was also lower than the utility obtained when the EuroQol was completed by stroke survivors in 1 study.1 For minor stroke, the utility was fairly similar to that elicited from healthy participants or patients at risk for stroke. Unfortunately, some items (eg, anxiety/depression) could not be scored unambiguously.6 We solved this problem by entering the extreme values in the range (including the score for "I am not anxious or depressed" and the score for "I am extremely anxious or depressed"), after which the utility of major stroke ranged from -0.30 to 0.20. It has been shown that EuroQol is a valid measure of health-related quality of life after stroke and is able to discriminate between various stroke states.19 The most likely explanation of the discrepancy may be that anxiety, depression, and pain or discomfort were not included in the health state descriptions of the included studies assessing utilities directly. Only Bosworth et al20 stratified their study population according to the presence of depression. Depressed stroke survivors assigned a mean utility of 0.61 to their health state compared with 0.79 for nondepressed patients. Emotional disorders such as depression are frequently present in the year after stroke.21 Therefore, inclusion of depression in the description of a health state after major stroke should be considered.
Conclusions
As argued before, TTO utilities may be least prone to
biases, and utilities for clinical decision analyses may be
best elicited from patients at
risk.8 These observations
imply that a utility of 0.55 is reasonable for minor stroke and a
utility of 0.25 is reasonable for major stroke. For cost-effectiveness
analyses from the societal perspective, Gold et
al8 argue that
utilities should be elicited from the general public, preferably a
health state classification system, such as HUI or EuroQol. Since the
EuroQol is based on the TTO, a utility between 0.60 and 0.70 seems
reasonable for minor stroke, while a utility between 0 and 0.30 should
be considered for major stroke. If a very severe stroke state
(including a severe motor and language deficit) is to be included in
the analysis, a utility of zero or below zero could be
considered.
| Acknowledgments |
|---|
Received October 17, 2000; revision received March 5, 2001; accepted March 5, 2001.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. J. McLernon, J. Dillon, and P. T. Donnan Systematic Review: Health-State Utilities in Liver Disease: A Systematic Review Med Decis Making, July 1, 2008; 28(4): 582 - 592. [Abstract] [PDF] |
||||
![]() |
J. P. Greving, E. Buskens, H. Koffijberg, and A. Algra Cost-Effectiveness of Aspirin Treatment in the Primary Prevention of Cardiovascular Disease Events in Subgroups Based on Age, Gender, and Varying Cardiovascular Risk Circulation, June 3, 2008; 117(22): 2875 - 2883. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J.H. Wermer, H. Koffijberg, I. C. van der Schaaf, and For the ASTRA Study Group Effectiveness and costs of screening for aneurysms every 5 years after subarachnoid hemorrhage Neurology, May 27, 2008; 70(22): 2053 - 2062. [Abstract] [Full Text] [PDF] |
||||
![]() |
H TAKAO, T NOJO, and K OHTOMO Treatment of ruptured intracranial aneurysms: a decision analysis Br. J. Radiol., April 1, 2008; 81(964): 299 - 303. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Takao and T. Nojo Treatment of Unruptured Intracranial Aneurysms: Decision and Cost-effectiveness Analysis Radiology, September 1, 2007; 244(3): 755 - 766. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Regier, R. Sunderji, L. D. Lynd, K. Gin, and C. A. Marra Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. Can. Med. Assoc. J., June 20, 2006; 174(13): 1847 - 1852. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Corrado, M. Rizzo, R. Tantillo, I. Muratori, F. Bonura, G. Vitale, and S. Novo Markers of Inflammation and Infection Influence the Outcome of Patients With Baseline Asymptomatic Carotid Lesions: A 5-Year Follow-Up Study Stroke, February 1, 2006; 37(2): 482 - 486. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Holloway, C. G. Benesch, W. S. Burgin, and J. B. Zentner Prognosis and Decision Making in Severe Stroke JAMA, August 10, 2005; 294(6): 725 - 733. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Brown, R. D. Chervin, S. L. Hickenbottom, K. M. Langa, and L. B. Morgenstern Screening for Obstructive Sleep Apnea in Stroke Patients: A Cost-Effectiveness Analysis Stroke, June 1, 2005; 36(6): 1291 - 1293. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. King Jr, J. Tsevat, and M. S. Roberts Preference-Based Quality of Life in Patients With Cerebral Aneurysms Stroke, February 1, 2005; 36(2): 303 - 309. [Abstract] [Full Text] [PDF] |
||||
![]() |
Submacular Surgery Trials Research Group Patients' Perceptions of the Value of Current Vision: Assessment of Preference Values Among Patients With Subfoveal Choroidal Neovascularization--The Submacular Surgery Trials Vision Preference Value Scale: SST Report No. 6 Arch Ophthalmol, December 1, 2004; 122(12): 1856 - 1867. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Wardlaw, J. Seymour, J. Cairns, S. Keir, S. Lewis, and P. Sandercock Immediate Computed Tomography Scanning of Acute Stroke Is Cost-Effective and Improves Quality of Life Stroke, November 1, 2004; 35(11): 2477 - 2483. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Sturm, G. A. Donnan, H. M. Dewey, R. A. L. Macdonell, A. K. Gilligan, V. Srikanth, and A. G. Thrift Quality of Life After Stroke: The North East Melbourne Stroke Incidence Study (NEMESIS) Stroke, October 1, 2004; 35(10): 2340 - 2345. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. F. Col, G. Weber, A. Stiggelbout, J. Chuo, R. D'Agostino, and P. Corso Short-term Menopausal Hormone Therapy for Symptom Relief: An Updated Decision Model Arch Intern Med, August 9, 2004; 164(15): 1634 - 1640. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sandercock, E. Berge, M. Dennis, J. Forbes, P. Hand, J. Kwan, S. Lewis, R. Lindley, A. Neilson, and J. Wardlaw Cost-Effectiveness of Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke Assessed by a Model Based on UK NHS Costs Stroke, June 1, 2004; 35(6): 1490 - 1497. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J.H. Wermer, E. Buskens, I. C. van der Schaaf, P. M.M. Bossuyt, and G. J.E. Rinkel Yield of screening for new aneurysms after treatment for subarachnoid hemorrhage Neurology, February 10, 2004; 62(3): 369 - 375. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Stahl, K. L. Furie, S. Gleason, and G. S. Gazelle Stroke: Effect of Implementing an Evaluation and Treatment Protocol Compliant with NINDS Recommendations Radiology, September 1, 2003; 228(3): 659 - 668. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Sturm, R. H. Osborne, H. M. Dewey, G. A. Donnan, R. A.L. Macdonell, and A. G. Thrift Brief Comprehensive Quality of Life Assessment After Stroke: The Assessment of Quality of Life Instrument in the North East Melbourne Stroke Incidence Study (NEMESIS) Stroke, December 1, 2002; 33(12): 2888 - 2894. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Chakravorty, R.M. Cayton, and A. Szczepura Health utilities in evaluating intervention in the sleep apnoea/hypopnoea syndrome Eur. Respir. J., November 1, 2002; 20(5): 1233 - 1238. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. N. Post, J. Kievit, J. M. van Baalen, W. B. van den Hout, and J. H. van Bockel Routine Duplex Surveillance Does Not Improve the Outcome After Carotid Endarterectomy: A Decision and Cost Utility Analysis Stroke, March 1, 2002; 33(3): 749 - 755. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |